


<b>Product Name</b>	: MK-8353 hydrochloride
<b>Synonyms</b>	: MK8353
<b>Cat No.</b>	: M13053
<b>CAS Number</b>	: 1951448-73-9
<b>Molecular Formula</b>	: C37H42ClN9O3S
<b>Formula Weight</b>	: 728.31
<b>Chemical Name</b>	: (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide hydrochloride
<b>Description</b>	MK-8353 hydrochloride (SCH-900353) is a highly potent, orally bioavailable, dual-specificity ERK1/2 inhibitor with IC50 of 23.0/8.8 nM, respectively; inhibits nonactivated ERK2 with IC50 of 0.5 nM, demonstrates excellent kinase selectivity over a 227-human kinase panel; decreases pERK1, pERK2, and ribosomal S6 kinase (pRSK) proteins, with complete suppression of pERK1 and pERK2 observed at 30 nM in A2058 cells, inhibits the in vitro proliferation of a panel of BRAFV600-mutant and RAS-mutant cancer cell lines; exhibits in vivo antitumor activity against BRAFV600 mutant Colo-205 colon cancer model and the BRAFV600 mutant SK-MEL-28 melanoma model. Colon Cancer Phase 1 Clinical
<b>Pathway</b>	: MAPK/ERK Signaling
<b>Target</b>	: ERK
<b>Receptor</b>	: ERK
<b>Solubility</b>	: —
<b>SMILES</b>	: —
<b>Storage</b>	: (-20°C)
<b>Stability</b>	: ≥ 2 years
<b>Reference</b>	:



1. Moschos SJ, et al. JCI Insight. 2018 Feb 22;3(4). pii: 92352.